Performance of Activities. In the event of a termination, (a) Investigator will immediately stop enrolling subjects into the Study and cease conducting Study procedures and treatment with the Study Drug on subjects already entered into the Study, to the extent medically advisable, and (b) Institution and/or Investigator will (i) furnish to Sponsor all Study Data and all CRFs, completed or partially complete, as of the effective date of termination, and (ii) return to Sponsor all Materials (defined below) that were furnished to Institution or Investigator, in accordance with Sponsor’s instruction, except for records or samples which the Institution and/or Investigator is required by law to retain. Within thirty (30) days of termination of this Agreement or completion of the Study (whichever comes first), Investigator will submit final written reports to Sponsor, which reports shall be consistent with industry standards and any criteria or requirements therefore specified in the Protocol. After termination of this Agreement or suspension of the Study at the Institution for any reason, all Parties shall continue activities under this Agreement solely as deemed necessary by mutual written agreement of the Parties based on reasonable medical judgment to protect the health of subjects participating in the Study. This Section 2.5 survives termination of this Agreement.
Appears in 2 contracts